ClinicalTrials.gg
CompletedNCT01375777MENDELUpdated Nov 8, 2022Results posted

Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels

A Phase 2 interventional study of Evolocumab and Ezetimibe in Hyperlipidemia, sponsored by Amgen. Completed at 58 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-11-08.

Sponsored by Amgen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
411
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing evolocumab in Hyperlipidemias — none open to participants now, none under way, none of them phase 3. evolocumab · Hyperlipidemias.

Enrollment
8th of 21
411 · median 307
Started
2011
with 2 others
Phase 2
3 of 21
none open now
Registered
2nd of 21
by date
Lead sponsor
16 of 21
Amgen

Among the 21 studies testing evolocumab in Hyperlipidemias, this one is the 8th largest by enrollment, is one of 3 that started in 2011, is one of 3 in phase 2, and was the 2nd registered.

Hyperlipidemias

862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.

Browse Hyperlipidemias studies →

Open to participants now

None of the 21 studies testing evolocumab in Hyperlipidemias is open now. The open studies under Hyperlipidemias, anywhere →

About evolocumab

evolocumab: first FDA approval 2015 (REPATHA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 21 studies testing evolocumab in Hyperlipidemias as a file.
02

Study summary

The primary objective was to evaluate the effect of 12 weeks of subcutaneous evolocumab (AMG 145) every 2 weeks (Q2W) or every 4 weeks (Q4W), compared with placebo, on the percent change from baseline in LDL-C when used as monotherapy in adults with hypercholesterolemia.

03

Conditions studied

  • Hyperlipidemia

Keywords

  • High cholesterol
  • Proprotein convertase subtilisin/kexin type 9 (PCSK9)
  • Treatment for high cholesterol
  • Lowering cholesterol
  • Lowering high cholesterol
  • Hypercholesterolemia
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female ≥ 18 to ≤ 75 years of age
  • Low density lipoprotein cholesterol (LDL-C) ≥ 100 mg/dL and \< 190 mg/dL
  • Framingham risk score of 10% or less
  • Fasting triglycerides \< 400 mg/dL

Exclusion criteria

Exclusion Criteria:

  • History of coronary heart disease
  • (NYHA) II - IV heart failure
  • Uncontrolled cardiac arrhythmia
  • Uncontrolled hypertension
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
411 participants (actual)

Study arms

  • Placebo comparator
    Placebo Q2W

    Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.

    Other: Placebo to Evolocumab

  • Placebo comparator
    Placebo Q4W

    Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks.

    Other: Placebo to Evolocumab

  • Active comparator
    Ezetimibe

    Participants received 10 mg ezetimibe orally once a day for 12 weeks.

    Drug: Ezetimibe

  • Experimental
    Evolocumab 70 mg Q2W

    Participants received 70 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.

    Biological: Evolocumab

  • Experimental
    Evolocumab 105 mg Q2W

    Participants received 105 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.

    Biological: Evolocumab

  • Experimental
    Evolocumab 140 mg Q2W

    Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.

    Biological: Evolocumab

  • Experimental
    Evolocumab 280 mg Q4W

    Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.

    Biological: Evolocumab

  • Experimental
    Evolocumab 350 mg Q4W

    Participants received 350 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.

    Biological: Evolocumab

  • Experimental
    Evolocumab 420 mg Q4W

    Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.

    Biological: Evolocumab

Interventions

  • BiologicalEvolocumab

    Administered by subcutaneous injection

    Also known as: AMG 145, Repatha

  • Administered orally once a day

    Also known as: Zetia

  • OtherPlacebo to Evolocumab

    Administered by subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12

    LDL-C was measured using ultracentrifugation.

    Time frame: Baseline and Week 12

Secondary outcomes

  1. Change From Baseline in LDL-C at Week 12

    LDL-C was measured using ultracentrifugation.

    Time frame: Baseline and Week 12

  2. Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12

    Time frame: Baseline and Week 12

  3. Percent Change From Baseline in Apolipoprotein B at Week 12

    Time frame: Baseline and Week 12

  4. Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at Week 12

    Time frame: Baseline and Week 12

  5. Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A-1 Ratio at Week 12

    Time frame: Baseline and Week 12

07

Results

Posted Oct 5, 2015

Participant flow

This study enrolled adults 18 - 75 years with fasting low-density lipoprotein cholesterol (LDL-C) ≥ 100 mg/dL and \< 190 mg/dL, fasting triglycerides ≤ 400 mg/dL and a National Cholesterol Education Program Adult Treatment Panel III Framingham risk score of 10% or less. First patient enrolled 06 July 2011, last patient enrolled 25 November 2011.

Participant flow — Overall Study
MilestonePlacebo Q2WPlacebo Q4WEzetimibeEvolocumab 70 mg Q2WEvolocumab 105 mg Q2WEvolocumab 140 mg Q2WEvolocumab 280 mg Q4WEvolocumab 350 mg Q4WEvolocumab 420 mg Q4W
Started464546454645464646
Received treatment454545454645454545
Completed444245454544444444
Not completed231011222
Withdrew: Withdrawal by subject021011121
Withdrew: Lost to follow-up100000100
Withdrew: Other110000001

Outcome measures

PrimaryPercent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12

LDL-C was measured using ultracentrifugation.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12
percent changePlacebo Q2WPlacebo Q4WEzetimibeEvolocumab 70 mg Q2WEvolocumab 105 mg Q2WEvolocumab 140 mg Q2WEvolocumab 280 mg Q4WEvolocumab 350 mg Q4WEvolocumab 420 mg Q4W
Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12-3.71 ± 2.664.54 ± 2.64-14.26 ± 2.60-40.98 ± 2.64-43.87 ± 2.60-50.93 ± 2.66-39.02 ± 2.57-43.20 ± 2.57-47.98 ± 2.58
Statistical analysis
  • Placebo Q2W vs Evolocumab 140 mg Q2W · ANCOVA · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -47.23 · 95% CI -54.52 to -39.93Placebo is the reference
  • Placebo Q2W vs Evolocumab 105 mg Q2W · ANCOVA · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -40.17 · 95% CI -47.38 to -32.95Placebo is the reference
  • Placebo Q2W vs Evolocumab 70 mg Q2W · ANCOVA · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -32.27 · 95% CI -44.53 to -30.02Placebo is the reference
  • Placebo Q4W vs Evolocumab 420 mg Q4W · ANCOVA · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -52.53 · 95% CI -59.67 to -45.38Placebo is the reference
  • Placebo Q4W vs Evolocumab 350 mg Q4W · ANCOVA · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -47.74 · 95% CI -54.89 to -40.60Placebo is the reference
  • Placebo Q4W vs Evolocumab 280 mg Q4W · ANCOVA · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -43.57 · 95% CI -50.71 to -36.42Placebo is the reference
SecondaryChange From Baseline in LDL-C at Week 12

LDL-C was measured using ultracentrifugation.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · mg/dL
Change From Baseline in LDL-C at Week 12
mg/dLPlacebo Q2WPlacebo Q4WEzetimibeEvolocumab 70 mg Q2WEvolocumab 105 mg Q2WEvolocumab 140 mg Q2WEvolocumab 280 mg Q4WEvolocumab 350 mg Q4WEvolocumab 420 mg Q4W
Change From Baseline in LDL-C at Week 12-3.4 ± 3.97.3 ± 3.7-19.2 ± 3.6-55.7 ± 3.7-66.0 ± 3.7-69.3 ± 3.6-53.5 ± 3.6-56.7 ± 3.6-65.0 ± 3.6
Statistical analysis
  • Placebo Q2W vs Evolocumab 140 mg Q2W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -65.9 · 95% CI -76.3 to -55.6Placebo is the reference
  • Placebo Q2W vs Evolocumab 105 mg Q2W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -62.7 · 95% CI -73.2 to -52.2Placebo is the reference
  • Placebo Q2W vs Evolocumab 70 mg Q2W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -52.3 · 95% CI -62.7 to -41.9Placebo is the reference
  • Placebo Q4W vs Evolocumab 420 mg Q4W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -72.3 · 95% CI -82.2 to -62.4Placebo is the reference
  • Placebo Q4W vs Evolocumab 350 mg Q4W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -63.9 · 95% CI -73.9 to -54.0Placebo is the reference
  • Placebo Q4W vs Evolocumab 280 mg Q4W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -60.8 · 95% CI -70.7 to -50.9Placebo is the reference
SecondaryPercent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12
Time frame:
Baseline and Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12
percent changePlacebo Q2WPlacebo Q4WEzetimibeEvolocumab 70 mg Q2WEvolocumab 105 mg Q2WEvolocumab 140 mg Q2WEvolocumab 280 mg Q4WEvolocumab 350 mg Q4WEvolocumab 420 mg Q4W
Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12-2.89 ± 2.40-0.25 ± 2.30-15.53 ± 2.36-37.95 ± 2.38-39.68 ± 2.34-48.04 ± 2.40-37.94 ± 2.24-42.14 ± 2.24-47.36 ± 2.25
Statistical analysis
  • Placebo Q2W vs Evolocumab 140 mg Q2W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -45.15 · 95% CI -51.72 to -38.58Placebo is the reference
  • Placebo Q2W vs Evolocumab 105 mg Q2W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -36.79 · 95% CI -43.29 to -30.29Placebo is the reference
  • Placebo Q2W vs Evolocumab 70 mg Q2W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -35.06 · 95% CI -41.59 to -28.52Placebo is the reference
  • Placebo Q4W vs Evolocumab 420 mg Q4W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -47.11 · 95% CI -53.33 to -40.89Placebo is the reference
  • Placebo Q4W vs Evolocumab 350 mg Q4W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -41.89 · 95% CI -48.11 to -35.67Placebo is the reference
  • Placebo Q4W vs Evolocumab 280 mg Q4W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -37.70 · 95% CI -43.92 to -31.47Placebo is the reference
SecondaryPercent Change From Baseline in Apolipoprotein B at Week 12
Time frame:
Baseline and Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apolipoprotein B at Week 12
percent changePlacebo Q2WPlacebo Q4WEzetimibeEvolocumab 70 mg Q2WEvolocumab 105 mg Q2WEvolocumab 140 mg Q2WEvolocumab 280 mg Q4WEvolocumab 350 mg Q4WEvolocumab 420 mg Q4W
Percent Change From Baseline in Apolipoprotein B at Week 12-0.33 ± 2.280.19 ± 2.28-11.17 ± 2.19-32.66 ± 2.26-36.20 ± 2.23-44.52 ± 2.28-33.04 ± 2.21-37.73 ± 2.21-42.29 ± 2.22
Statistical analysis
  • Placebo Q2W vs Evolocumab 140 mg Q2W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -44.19 · 95% CI -50.45 to -37.94Placebo is the reference
  • Placebo Q2W vs Evolocumab 105 mg Q2W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -35.87 · 95% CI -42.06 to -29.69Placebo is the reference
  • Placebo Q2W vs Evolocumab 70 mg Q2W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -32.33 · 95% CI -38.55 to -26.11Placebo is the reference
  • Placebo Q4W vs Evolocumab 420 mg Q4W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -42.48 · 95% CI -48.63 to -36.32Placebo is the reference
  • Placebo Q4W vs Evolocumab 350 mg Q4W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -37.92 · 95% CI -44.07 to -31.76Placebo is the reference
  • Placebo Q4W vs Evolocumab 280 mg Q4W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -33.22 · 95% CI -39.38 to -27.07Placebo is the reference
SecondaryPercent Change From Baseline in Total Cholesterol/HDL-C Ratio at Week 12
Time frame:
Baseline and Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at Week 12
percent changePlacebo Q2WPlacebo Q4WEzetimibeEvolocumab 70 mg Q2WEvolocumab 105 mg Q2WEvolocumab 140 mg Q2WEvolocumab 280 mg Q4WEvolocumab 350 mg Q4WEvolocumab 420 mg Q4W
Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at Week 12-1.21 ± 2.17-3.39 ± 2.11-16.65 ± 1.99-30.07 ± 2.15-33.13 ± 2.12-38.70 ± 2.17-32.07 ± 2.05-34.60 ± 2.05-39.97 ± 2.06
Statistical analysis
  • Placebo Q2W vs Evolocumab 140 mg Q2W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -37.49 · 95% CI -43.43 to -31.54Placebo is the reference
  • Placebo Q2W vs Evolocumab 105 mg Q2W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -31.92 · 95% CI -37.79 to -26.04Placebo is the reference
  • Placebo Q2W vs Evolocumab 70 mg Q2W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -28.86 · 95% CI -34.77 to -22.95Placebo is the reference
  • Placebo Q4W vs Evolocumab 420 mg Q4W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -36.58 · 95% CI -42.29 to -30.88Placebo is the reference
  • Placebo Q4W vs Evolocumab 350 mg Q4W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -31.21 · 95% CI -36.92 to -25.51Placebo is the reference
  • Placebo Q4W vs Evolocumab 280 mg Q4W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -28.69 · 95% CI -34.39 to -22.98Placebo is the reference
SecondaryPercent Change From Baseline in Apolipoprotein B/Apolipoprotein A-1 Ratio at Week 12
Time frame:
Baseline and Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A-1 Ratio at Week 12
percent changePlacebo Q2WPlacebo Q4WEzetimibeEvolocumab 70 mg Q2WEvolocumab 105 mg Q2WEvolocumab 140 mg Q2WEvolocumab 280 mg Q4WEvolocumab 350 mg Q4WEvolocumab 420 mg Q4W
Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A-1 Ratio at Week 122.03 ± 2.400.14 ± 2.46-12.35 ± 2.33-32.80 ± 2.38-38.30 ± 2.35-48.13 ± 2.40-36.10 ± 2.39-40.43 ± 2.39-45.33 ± 2.40
Statistical analysis
  • Placebo Q2W vs Evolocumab 140 mg Q2W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -50.16 · 95% CI -56.75 to -43.58Placebo is the reference
  • Placebo Q2W vs Evolocumab 105 mg Q2W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -40.33 · 95% CI -46.84 to -33.82Placebo is the reference
  • Placebo Q2W vs Evolocumab 70 mg Q2W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -34.83 · 95% CI -41.38 to -28.28Placebo is the reference
  • Placebo Q4W vs Evolocumab 420 mg Q4W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -45.47 · 95% CI -52.12 to -38.82Placebo is the reference
  • Placebo Q4W vs Evolocumab 350 mg Q4W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -40.57 · 95% CI -47.22 to -33.92Placebo is the reference
  • Placebo Q4W vs Evolocumab 280 mg Q4W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -36.25 · 95% CI -42.90 to -29.60Placebo is the reference

Adverse events

Collected over 12 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Q2W—0/45 (0%)10/45 (22.2%)
Placebo Q4W—0/45 (0%)10/45 (22.2%)
Ezetimibe—0/45 (0%)14/45 (31.1%)
Evolocumab 70 mg Q2W—0/45 (0%)11/45 (24.4%)
Evolocumab 105 mg Q2W—1/46 (2.2%)11/46 (23.9%)
Evolocumab 140 mg Q2W—1/45 (2.2%)14/45 (31.1%)
Evolocumab 280 mg Q4W—0/45 (0%)7/45 (15.6%)
Evolocumab 350 mg Q4W—1/45 (2.2%)11/45 (24.4%)
Evolocumab 420 mg Q4W—0/45 (0%)9/45 (20%)
Most frequent serious events
Most frequent serious events
EventPlacebo Q2WPlacebo Q4WEzetimibeEvolocumab 70 mg Q2WEvolocumab 105 mg Q2WEvolocumab 140 mg Q2WEvolocumab 280 mg Q4WEvolocumab 350 mg Q4WEvolocumab 420 mg Q4W
AppendicitisInfections and infestations0/450/450/450/450/461/450/450/450/45
Humerus fractureInjury, poisoning and procedural complications0/450/450/450/450/460/450/451/450/45
IgA nephropathyRenal and urinary disorders0/450/450/450/451/460/450/450/450/45
Most frequent other events
Most frequent other events
EventPlacebo Q2WPlacebo Q4WEzetimibeEvolocumab 70 mg Q2WEvolocumab 105 mg Q2WEvolocumab 140 mg Q2WEvolocumab 280 mg Q4WEvolocumab 350 mg Q4WEvolocumab 420 mg Q4W
Upper respiratory tract infectionInfections and infestations5/452/455/453/452/462/453/453/454/45
NasopharyngitisInfections and infestations3/450/454/452/452/461/451/453/452/45
Back painMusculoskeletal and connective tissue disorders0/454/451/451/451/462/451/451/453/45
DiarrhoeaGastrointestinal disorders0/453/451/452/450/462/450/453/453/45
NauseaGastrointestinal disorders0/451/450/450/450/463/451/450/451/45
FatigueGeneral disorders3/451/452/450/451/463/450/451/452/45
HeadacheNervous system disorders3/451/451/453/452/462/450/450/451/45
Oropharyngeal painRespiratory, thoracic and mediastinal disorders2/451/451/453/451/462/451/450/450/45
Injection site indurationGeneral disorders0/450/450/450/453/461/450/451/450/45
Sinus congestionRespiratory, thoracic and mediastinal disorders1/451/450/452/453/462/451/450/450/45

Baseline characteristics

Full analysis set (all randomized participants who received at least 1 dose of investigational product).

Age, Continuous
Age, Continuous(years)Placebo Q2WPlacebo Q4WEzetimibeEvolocumab 70 mg Q2WEvolocumab 105 mg Q2WEvolocumab 140 mg Q2WEvolocumab 280 mg Q4WEvolocumab 350 mg Q4WEvolocumab 420 mg Q4WTotal
Mean52.5 ± 9.850.7 ± 12.650.0 ± 12.050.9 ± 12.948.3 ± 11.852.8 ± 11.649.3 ± 10.350.9 ± 13.150.1 ± 12.050.6 ± 11.8
Sex: Female, Male
Sex: Female, Male(Participants)Placebo Q2WPlacebo Q4WEzetimibeEvolocumab 70 mg Q2WEvolocumab 105 mg Q2WEvolocumab 140 mg Q2WEvolocumab 280 mg Q4WEvolocumab 350 mg Q4WEvolocumab 420 mg Q4WTotal
Female253026303336283326267
Male20151915139171219139
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Placebo Q2WPlacebo Q4WEzetimibeEvolocumab 70 mg Q2WEvolocumab 105 mg Q2WEvolocumab 140 mg Q2WEvolocumab 280 mg Q4WEvolocumab 350 mg Q4WEvolocumab 420 mg Q4WTotal
American Indian or Alaska Native0001001103
Asian21133212217
Black or African American879754861064
Native Hawaiian or Other Pacific Islander0100100002
White353635333739353633319
Other0001000001
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Placebo Q2WPlacebo Q4WEzetimibeEvolocumab 70 mg Q2WEvolocumab 105 mg Q2WEvolocumab 140 mg Q2WEvolocumab 280 mg Q4WEvolocumab 350 mg Q4WEvolocumab 420 mg Q4WTotal
Hispanic or Latino565558751056
ot Hispanic or Latino403940404137384035350
Stratification Factor: LDL-C level
Stratification Factor: LDL-C level(participants)Placebo Q2WPlacebo Q4WEzetimibeEvolocumab 70 mg Q2WEvolocumab 105 mg Q2WEvolocumab 140 mg Q2WEvolocumab 280 mg Q4WEvolocumab 350 mg Q4WEvolocumab 420 mg Q4WTotal
< 130 mg/dL151415141514151514131
≥ 130 mg/dL303130313131303031275
LDL-C Concentration
LDL-C Concentration(mg/dL)Placebo Q2WPlacebo Q4WEzetimibeEvolocumab 70 mg Q2WEvolocumab 105 mg Q2WEvolocumab 140 mg Q2WEvolocumab 280 mg Q4WEvolocumab 350 mg Q4WEvolocumab 420 mg Q4WTotal
Mean147.0 ± 21.0142.3 ± 24.3144.2 ± 25.8143.1 ± 21.7141.5 ± 22.3139.8 ± 21.1141.1 ± 21.8136.6 ± 20.8138.9 ± 21.9141.6 ± 22.3
Non-High-Density Lipoprotein Cholesterol (non-HDL-C) Concentration
Non-High-Density Lipoprotein Cholesterol (non-HDL-C) Concentration(mg/dL)Placebo Q2WPlacebo Q4WEzetimibeEvolocumab 70 mg Q2WEvolocumab 105 mg Q2WEvolocumab 140 mg Q2WEvolocumab 280 mg Q4WEvolocumab 350 mg Q4WEvolocumab 420 mg Q4WTotal
Mean173.8 ± 30.5169.1 ± 27.7170.0 ± 32.0169.0 ± 24.5169.2 ± 24.3163.8 ± 23.7166.3 ± 27.8161.1 ± 26.1167.9 ± 29.6167.8 ± 27.4
Apolipoprotein B Concentration
Apolipoprotein B Concentration(mg/dL)Placebo Q2WPlacebo Q4WEzetimibeEvolocumab 70 mg Q2WEvolocumab 105 mg Q2WEvolocumab 140 mg Q2WEvolocumab 280 mg Q4WEvolocumab 350 mg Q4WEvolocumab 420 mg Q4WTotal
Mean111.7 ± 17.1110.4 ± 17.2109.9 ± 17.7108.7 ± 15.7108.5 ± 15.2107.2 ± 16.3109.2 ± 15.7105.8 ± 15.9110.2 ± 18.4109.1 ± 16.5

2 further baseline measures are reported on the registry.

08

Study locations

58 sites
  • Research Site
    Birmingham, Alabama 35216, United States
  • Research Site
    Little Rock, Arkansas 72205, United States
  • Research Site
    Encinitas, California 92024, United States
  • Research Site
    Inglewood, California 90301, United States
  • Research Site
    San Diego, California 92111, United States
  • Research Site
    Tustin, California 92780, United States
  • Research Site
    DeLand, Florida 32720, United States
  • Research Site
    Jacksonville, Florida 32216, United States
  • Research Site
    Jacksonville, Florida 32223, United States
  • Research Site
    Miami, Florida 33143, United States
  • Research Site
    Miami, Florida 33144, United States
  • Research Site
    Ponte Vedra, Florida 32081, United States
  • Research Site
    Sanford, Florida 32771, United States
  • Research Site
    Decatur, Georgia 30035, United States
  • Research Site
    Chicago, Illinois 60610, United States
  • Research Site
    Indianapolis, Indiana 46260, United States
  • Research Site
    Louisville, Kentucky 40213, United States
  • Research Site
    Bethesda, Maryland 20817, United States
  • Research Site
    Brockton, Massachusetts 02301, United States
  • Research Site
    Brooklyn Center, Minnesota 55430, United States
  • Research Site
    Las Vegas, Nevada 89148, United States
  • Research Site
    Endwell, New York 13760, United States
  • Research Site
    New Windsor, New York 12553, United States
  • Research Site
    Raleigh, North Carolina 27609, United States
  • Research Site
    Raleigh, North Carolina 27612, United States
  • Research Site
    Fargo, North Dakota 58103, United States
  • Research Site
    Cincinnati, Ohio 45219, United States
  • Research Site
    Cincinnati, Ohio 45246, United States
  • Research Site
    Cleveland, Ohio 44122, United States
  • Research Site
    Norman, Oklahoma 73069, United States
  • Research Site
    Oklahoma City, Oklahoma 73103, United States
  • Research Site
    Duncansville, Pennsylvania 16635, United States
  • Research Site
    Mount Pleasant, South Carolina 29464, United States
  • Research Site
    Rapid City, South Dakota 57702, United States
  • Research Site
    Arlington, Texas 76014, United States
  • Research Site
    Boerne, Texas 78006, United States
  • Research Site
    San Antonio, Texas 78205, United States
  • Research Site
    Norfolk, Virginia 23502, United States
  • Research Site
    Richmond, Virginia 23294, United States
  • Research Site
    Renton, Washington 98057, United States
  • Research Site
    Seattle, Washington 98122, United States
  • Research Site
    Maroubra, New South Wales 2035, Australia
  • Research Site
    Carina Heights, Queensland 4152, Australia
  • Research Site
    Anthée, 5520, Belgium
  • Research Site
    Dour, 7370, Belgium
  • Research Site
    Gozee, 6534, Belgium
  • Research Site
    Gribomont, 6887, Belgium
  • Research Site
    Halen, 3545, Belgium
  • Research Site
    Ham, 3945, Belgium
  • Research Site
    Linkebeek, 1630, Belgium
  • Research Site
    Retie, 2470, Belgium
  • Research Site
    Bay Roberts, Newfoundland and Labrador A0A 1G0, Canada
  • Research Site
    Mount Pearl, Newfoundland and Labrador A1N 1W7, Canada
  • Research Site
    Toronto, Ontario M9W 4L6, Canada
  • Research Site
    Granby, Quebec J2G 8Z9, Canada
  • Research Site
    Aalborg, 9000, Denmark
  • Research Site
    Ballerup, 2750, Denmark
  • Research Site
    Vejle, 7100, Denmark
09

References and documents

Publications

  • Koren MJ, Scott R, Kim JB, Knusel B, Liu T, Lei L, Bolognese M, Wasserman SM. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet. 2012 Dec 8;380(9858):1995-2006. doi: 10.1016/S0140-6736(12)61771-1. Epub 2012 Nov 6. PubMed 23141812 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2011 to primary completion in Mar 2012, 7 months.

Results were first posted in Oct 2015, 3 years 7 months after primary completion. A results delay was requested in Mar 2013.

Of 30 phase 2 interventional studies under Hyperlipidemias, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 27. This study's 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2011
First posted
Jun 17, 2011
StartActual
Jul 6, 2011
Primary completionActual
Mar 2, 2012
CompletionActual
Mar 2, 2012
Results delay requested
Mar 26, 2013
Results first posted
Oct 5, 2015
Last update
Nov 8, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01375777
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Jun 17, 2011
Start date
Jul 6, 2011
Primary completion
Mar 2, 2012
Completion
Mar 2, 2012
Results posted
Oct 5, 2015
Last update
Nov 8, 2022

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Evolocumab

Start the discussion